Author + information
- Arif Al Nooryani1,
- Wael Elabbassi2,
- Marija Markovic3,
- amit bhatia4,
- Galal Kerfes5,
- Loai Abudaqa6,
- Anoop Mansoor7,
- bassam al baba8 and
- Nagwa Abdel Rahman9
- 1Al-Qassimi Hospital, Sharjah, United Arab Emirates
- 2Alas sims hospital, Sharjah, United Arab Emirates
- 3Al Qassimi Hospital, Dubai, United Arab Emirates
- 4al Qassimi Hospital, sharjah, United Arab Emirates
- 5The Everett Clinic, Everett, WA
- 6al Qassimi Hospital, Abu Dhabi, United Arab Emirates
- 7Medanta Super Speciality Hospital, Indore, Madhya Pradesh, India
- 8Al Qassimi Hospital, sharja, United Arab Emirates
- 9Cosmopolitan Hospital, Thiruvananthapuram, Kerala, India
The aim of this registry was to report initial experience with the routine use of Absorb bioresorbable scaffold (BRS) in the first 300 consecutive patients treated with PCI.
The study was a retrospective, single PCI centre registry using Absorb BRS in an all-comers population including patients with both stable angina and acute coronary syndrome. Starting from March 2012, a total of 300 patients (mean age 54±9 years, 67% male) were treated with Absorb BVS at Al Qassimi Hospital, Sharjah, UAE.
CAD risk factors included high proportion of patients with diabetes mellitus (47%), then hypertension (54%), hyperlipidemia (47%), and active smoking (41%). Absorb BVS was implanted in 65% of patients with stable angina, and 35% of patients with acute coronary syndrome, including 11% of patients with STEMI. All lesion and scaffold size evaluation was based on visual assessment, with adequate lesion preparation of the lesion in 90% of the patients, and postdilatation in 78% of the patients. Moderate-to-severe calcifications of treated coronary arteries were present in 13% of patients. In 20% of patients Absorb BRS was implanted in patients with true bifurcation, and 12% of patients after successful opening of acutely of chronically occluded vessel. Minimal luminal diameter, and % diameter stenosis increased from 0.90±0.56mm to 2,41±0.51mm, and 67±20% to 11±9%, respectively. In 11 patients residual dissection after BRS implantation was observed (in 2 treated with additional PCI), and in 5 patients acute scaffold thrombosis developed. Procedural success was achieved in 97% of patients.
Our initial experience with Absorb BVS implantation in an all-comers population demonstrated excellent feasibility, safety and performance in patients with a broad spectrum of patients with coronary artery disease.
CORONARY: Bioresorbable Vascular Scaffolds